Innoviva Inc (INVA)

NASDAQ
Currency in USD
18.58
+0.13(+0.70%)
Closed
After Hours
18.580.00(0.00%)
INVA Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
18.4418.61
52 wk Range
14.3321.28
Key Statistics
Edit
Prev. Close
18.45
Open
18.52
Day's Range
18.44-18.61
52 wk Range
14.33-21.28
Volume
606.5K
Average Volume (3m)
658.58K
1-Year Change
14.27%
Book Value / Share
10.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INVA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
19.00
Upside
+2.26%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Innoviva Inc Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Employees
112

Compare INVA to Peers and Sector

Metrics to compare
INVA
Peers
Sector
Relationship
P/E Ratio
18.0x−1.2x−0.6x
PEG Ratio
0.390.000.00
Price/Book
1.7x0.7x2.6x
Price / LTM Sales
3.3x3.1x3.1x
Upside (Analyst Target)
2.3%222.6%54.8%
Fair Value Upside
Unlock11.3%7.9%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 19.00

(+2.26% Upside)

Earnings

Latest Release
Nov 06, 2024
EPS / Forecast
0.02 / 0.27
Revenue / Forecast
89.51M / 76.91M
EPS Revisions
Last 90 days

People Also Watch

140.55
BIIB
-0.48%
429.03
MSFT
+1.05%
57.97
MCHP
+3.17%
225.94
AMZN
+2.39%
71.61
ACLS
-0.51%

FAQ

What Is the Innoviva (INVA) Stock Price Today?

The Innoviva stock price today is 18.58

What Stock Exchange Does Innoviva Trade On?

Innoviva is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Innoviva?

The stock symbol for Innoviva is "INVA."

What Is the Innoviva Market Cap?

As of today, Innoviva market cap is 1.16B.

What is Innoviva Earnings Per Share?

The Innoviva EPS is 1.03.

What Is the Next Innoviva Earnings Date?

Innoviva will release its next earnings report on Feb 04, 2025.

From a Technical Analysis Perspective, Is INVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.